Deane Retirement Strategies Inc. Purchases 9,561 Shares of Johnson & Johnson (NYSE:JNJ)

Deane Retirement Strategies Inc. grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 48.9% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 29,113 shares of the company’s stock after purchasing an additional 9,561 shares during the quarter. Johnson & Johnson makes up approximately 2.1% of Deane Retirement Strategies Inc.’s holdings, making the stock its 16th biggest position. Deane Retirement Strategies Inc.’s holdings in Johnson & Johnson were worth $4,210,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the business. Twelve Points Wealth Management LLC lifted its position in Johnson & Johnson by 9.4% during the fourth quarter. Twelve Points Wealth Management LLC now owns 13,344 shares of the company’s stock valued at $1,930,000 after purchasing an additional 1,148 shares in the last quarter. Gateway Wealth Partners LLC raised its stake in shares of Johnson & Johnson by 5.3% in the fourth quarter. Gateway Wealth Partners LLC now owns 2,325 shares of the company’s stock worth $336,000 after buying an additional 116 shares during the period. Orca Wealth Management LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at about $276,000. Bensler LLC grew its stake in shares of Johnson & Johnson by 5.8% during the 4th quarter. Bensler LLC now owns 1,985 shares of the company’s stock valued at $287,000 after acquiring an additional 109 shares during the period. Finally, Jeppson Wealth Management LLC increased its holdings in Johnson & Johnson by 2.0% in the 4th quarter. Jeppson Wealth Management LLC now owns 14,341 shares of the company’s stock worth $2,074,000 after acquiring an additional 286 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling

In other news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Down 0.5 %

Shares of NYSE:JNJ opened at $152.09 on Friday. The company has a market cap of $366.17 billion, a price-to-earnings ratio of 22.87, a PEG ratio of 2.43 and a beta of 0.51. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The company has a 50-day moving average price of $147.67 and a 200 day moving average price of $156.07.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same period last year, the company earned $2.29 EPS. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. As a group, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.26%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Wells Fargo & Company decreased their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Stifel Nicolaus dropped their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Finally, Barclays lifted their target price on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research note on Tuesday. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $170.44.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.